Echopoint Medical Limited is a University College London (UCL) spin-out, which has developed core photonic sensor technology to greatly enhance the diagnosis and treatment of coronary heart disease.
Echopoint was founded upon the research of Dr Adrien Desjardins, Dr Malcolm Finlay, Dr Ioannis Papakonstantinou and Dr Richard Colchester. The core research has attracted grants totalling £5.8M during its development over a decade as well as generating over 50 peer reviewed publications.
Coronary Heart Disease (CHD) remains the leading cause of death worldwide, and 2.3 million people live with CHD in the UK. Echopoint’s technology uses multimodality fibre-optic sensing and tracking, and can be performed from miniaturised optical fibers, providing physicians with critical information and procedural metrics to significantly improve diagnosis and therapy for CHD and more.
